103 related articles for article (PubMed ID: 10353741)
1. Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia.
Li Q; Kopecky KJ; Mohan A; Willman CL; Appelbaum FR; Weick JK; Issa JP
Clin Cancer Res; 1999 May; 5(5):1077-84. PubMed ID: 10353741
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
[TBL] [Abstract][Full Text] [Related]
4. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
Gupta V; Chun K; Yi QL; Minden M; Schuh A; Wells R; Brandwein J
Cancer; 2005 May; 103(10):2082-90. PubMed ID: 15830348
[TBL] [Abstract][Full Text] [Related]
5. Patients with isolated trisomy 8 in acute myeloid leukemia are not cured with cytarabine-based chemotherapy: results from Cancer and Leukemia Group B 8461.
Byrd JC; Lawrence D; Arthur DC; Pettenati MJ; Tantravahi R; Qumsiyeh M; Stamberg J; Davey FR; Schiffer CA; Bloomfield CD
Clin Cancer Res; 1998 May; 4(5):1235-41. PubMed ID: 9607582
[TBL] [Abstract][Full Text] [Related]
6. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
7. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotyping is an independent factor for risk stratification in AML.
Repp R; Schaekel U; Helm G; Thiede C; Soucek S; Pascheberg U; Wandt H; Aulitzky W; Bodenstein H; Sonnen R; Link H; Ehninger G; Gramatzki M;
Cytometry B Clin Cytom; 2003 May; 53(1):11-9. PubMed ID: 12717686
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients.
de Bont ES; Fidler V; Meeuwsen T; Scherpen F; Hählen K; Kamps WA
Clin Cancer Res; 2002 Sep; 8(9):2856-61. PubMed ID: 12231527
[TBL] [Abstract][Full Text] [Related]
10. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.
Marcucci G; Mrózek K; Ruppert AS; Archer KJ; Pettenati MJ; Heerema NA; Carroll AJ; Koduru PR; Kolitz JE; Sterling LJ; Edwards CG; Anastasi J; Larson RA; Bloomfield CD
J Clin Oncol; 2004 Jun; 22(12):2410-8. PubMed ID: 15197203
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.
Kern W; Voskova D; Schoch C; Schnittger S; Hiddemann W; Haferlach T
Haematologica; 2004 May; 89(5):528-40. PubMed ID: 15136215
[TBL] [Abstract][Full Text] [Related]
12. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy in childhood acute myeloid leukemia.
Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
[TBL] [Abstract][Full Text] [Related]
14. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.
Byrd JC; Ruppert AS; Mrózek K; Carroll AJ; Edwards CG; Arthur DC; Pettenati MJ; Stamberg J; Koduru PR; Moore JO; Mayer RJ; Davey FR; Larson RA; Bloomfield CD
J Clin Oncol; 2004 Mar; 22(6):1087-94. PubMed ID: 15020610
[TBL] [Abstract][Full Text] [Related]
15. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Marcucci G; Mrózek K; Ruppert AS; Maharry K; Kolitz JE; Moore JO; Mayer RJ; Pettenati MJ; Powell BL; Edwards CG; Sterling LJ; Vardiman JW; Schiffer CA; Carroll AJ; Larson RA; Bloomfield CD
J Clin Oncol; 2005 Aug; 23(24):5705-17. PubMed ID: 16110030
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia.
Roberson JR; Onciu M; Pounds S; Rubnitz JE; Pui CH; Razzouk BI
Pediatr Blood Cancer; 2008 Mar; 50(3):542-8. PubMed ID: 17763467
[TBL] [Abstract][Full Text] [Related]
18. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia.
Rodrigues PC; Oliveira SN; Viana MB; Matsuda EI; Nowill AE; Brandalise SR; Yunes JA
Pediatr Blood Cancer; 2007 Aug; 49(2):133-8. PubMed ID: 16883592
[TBL] [Abstract][Full Text] [Related]
20. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
